title: Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial.
abstract: BACKGROUND
  Excessive body weight gain (BWG), hyperglycemia and dyslipidemia are important side effects of olanzapine. We assessed the effects of rosiglitazone on BWG, the insulin resistance index (HOMA-IR), lipids, glycated hemoglobin and fibrinogen in olanzapine-treated schizophrenia patients.
  
  
  METHODS
  Thirty patients taking olanzapine (10-20 mg daily for 8 months) were randomly allocated to rosiglitazone (n=15; 4 to 8 mg daily) or placebo (n=15) in a 12-week double-blind protocol. Anthropometric and biochemical variables were evaluated at baseline, weeks 6 and 12.
  
  
  RESULTS
  The rosiglitazone and placebo groups gained 3.2+/-4.5 and 2.2+/-2.3 kg, respectively (p=0.65). Insulin and the HOMA-IR significantly decreased after rosiglitazone (p<0.05). Rosiglitazone did not improve the lipid profile, fibrinogen and Hb1c levels.
  
  
  CONCLUSIONS
  The positive impact of rosiglitazone was limited to improved glycemic control. It cannot be recommended for metabolic control during olanzapine treatment.
authors.affiliation: Department of Physiology, Los Andes University Medical School, Mérida, Venezuela. trinbap@yahoo.com
authors.forename: T
authors.initials: T
authors.lastname: Baptista
authors.forename: N
authors.initials: N
authors.lastname: Rangel
authors.forename: Y
authors.initials: Y
authors.lastname: El Fakih
authors.forename: E
authors.initials: E
authors.lastname: Uzcátegui
authors.forename: T
authors.initials: T
authors.lastname: Galeazzi
authors.forename: S
authors.initials: S
authors.lastname: Beaulieu
authors.forename: E
authors.initials: E
authors.lastname: Araujo de Baptista
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001569:Benzodiazepines / Q000009:adverse effects*; D015992:Body Mass Index; D001835:Body Weight / Q000187:drug effects; D004311:Double-Blind Method; D005260:Female; D005340:Fibrinogen / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D008659:Metabolic Diseases / Q000139:chemically induced* / Q000188:drug therapy*; D008875:Middle Aged; D000077152:Olanzapine; D010865:Pilot Projects; D000077154:Rosiglitazone; D012559:Schizophrenia / Q000188:drug therapy; D013223:Statistics as Topic; D045162:Thiazolidinediones / Q000627:therapeutic use*
chemical_list: D014150:Antipsychotic Agents; D006454:Hemoglobins; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D001569:Benzodiazepines; D005340:Fibrinogen; D000077152:Olanzapine